Learn More
Cyclooxygenase-2 (COX-2) overexpression is associated with a poor prognosis in non-small-cell lung cancer (NSCLC) and may promote resistance to epidermal growth factor receptor inhibitors. This(More)
7528 Background: Apricoxib is a selective inhibitor of COX-2. The COX-2 pathway plays a key role in tumor growth, angiogenesis and resistance to therapy. In a phase I trial apricoxib and erlotinib(More)
  • 1